Hematological malignancies and autoimmune hemolytic anemia in systemic lupus erythematosus patients: A literature review
Open Access
- 8 June 2026
- journal article
- Published by Medical University of Silesia in Katowice in Annales Academiae Medicae Silesiensis
Abstract
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by immune dysregulation and a wide spectrum of clinical manifestations, including significant hematological involvement. The objective of this review was to summarize the epidemiology, pathogenic mechanisms, and treatment approaches for hematological malignancies (HMs) and autoimmune hemolytic anemia (AIHA) in patients with SLE, integrating recent advances in diagnosis and therapy. We conducted a narrative review of meta-analyses, large population-based studies, and translational research addressing lymphoma, leukemia, multiple myeloma, and AIHA in the context of SLE. Findings consistently demonstrate an increased standardized incidence ratio (SIR) for HMs, particularly non-Hodgkin’s lymphoma (SIR ≈ 5.7), with elevated risks also reported for Hodgkin lymphoma, leukemias (acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia), and multiple myeloma (SIR ≈ 1.5). Pathogenesis is multifactorial, involving chronic immune activation, Epstein-Barr virus reactivation, oxidative stress, impaired DNA repair, and cumulative exposure to alkylating agents. AIHA, most commonly warm-antibody mediated, represents an additional source of morbidity, often complicating treatment decisions. Corticosteroids remain the first-line therapy, while refractory disease benefits from rituximab or cytotoxic immunosuppressants. Novel therapeutic strategies, including complement inhibitors (sutimlimab, pegcetacoplan), Bruton tyrosine kinase inhibitors, and neonatal Fc receptor antagonists, are emerging as promising options to reduce relapse rates and steroid dependence. Early recognition, individualized immunosuppressive regimens, and incorporation of targeted therapies may improve survival and long-term outcomes in this high-risk population.Keywords
This publication has 84 references indexed in Scilit:
- Parsaclisib for the treatment of primary autoimmune hemolytic anemia: Results from a phase 2, open‐label studyAmerican Journal of Hematology, 2024
- Mixed autoimmune hemolytic anemia as the initial presentation of systemic lupus erythematosus: A case report and revieweJHaem, 2024
- Concomitant manifestations of systemic lupus erythematosus flare‐up and nodal marginal zone B‐cell lymphoma in a 41‐year‐old male patient: A challenging case reportClinical Case Reports, 2024
- Identification of the shared gene signatures and molecular pathways in systemic lupus erythematosus and diffuse large B‐cell lymphomaThe Journal of Gene Medicine, 2023
- The five major autoimmune diseases increase the risk of cancer: epidemiological data from a large‐scale cohort study in ChinaCancer Communications, 2022
- Refractory autoimmune hemolytic anemia in a systemic lupus erythematosus patient: A clinical case reportClinical Case Reports, 2022
- Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open‐label studyAmerican Journal of Hematology, 2022
- A Randomized, First‐in‐Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement PathwayClinical Pharmacology & Therapeutics, 2018
- Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus‐prone miceArthritis & Rheumatism, 2010
- An international cohort study of cancer in systemic lupus erythematosusArthritis & Rheumatism, 2005